IE 11 is not supported. For an optimal experience visit our site on another browser.

Apricus Biosciences to Present at the FSX Investor Conference in San Francisco on April 28, 2011

/ Source: GlobeNewswire

SAN DIEGO, April 27, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences ("Apricus Bio") (Nasdaq:APRI) today announced that Ed Cox, Vice President Corporate Development and Investor Relations, will present at the FSX (Financial Services Exchange, Inc.) investors conference being held at the Ritz Carlton in San Francisco from April 28-30, 2011. Mr. Cox's presentation is scheduled for tomorrow, April 28, 2011 and will not be available in live webcast, but a replay will be available on the Company's website.

FSX is the premier investment conference organization in the United States, hosting quarterly investment conferences around the country, providing opportunities for networking and one-on-one communication between independent broker/dealers and companies seeking exposure or funding. FSX conferences also provide a forum for direct investment programs, mutual funds, and asset management companies. For more information visit: .

About Apricus Biosciences

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.

For further information on Apricus Bio, visit and for information on its subsidiaries please visit or . You can also receive information at and .

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further develop products and product, to successfully commercialize such products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

CONTACT: Apricus Bio Contacts: Edward Cox, V.P. Investor Relations Apricus Biosciences (858) 848-4249 Apricus Bio Investor Relations: Paula Schwartz Rx Communications Group, LLC (917) 322-2216